Abstract
E2F1 induces apoptosis via both p53-dependent and p53-independent mechanisms. The direct targets in the p53-independent pathway remain enigmatic; however, the induction of this pathway does not require the transactivation domain of E2F1. Using cells that are defective in p53 activation, we show that E2F1 potently represses the expression of Mcl-1 – an anti-apoptotic Bcl-2 family member whose depletion results in apoptosis. We also show that this transcriptional repression is direct and dependent upon E2F1's DNA-binding domain, but does not require the transactivation domain of E2F1. Consistent with this DNA binding requirement of E2F1 to repress Mcl-1, we show that E2F1 binds to the Mcl-1 promoter both in vitro and in vivo, and have identified the DNA element (−143/−117) within this promoter that is required for E2F1 binding and repression. Additionally, cell lines constitutively expressing Mcl-1 are resistant to E2F1-mediated apoptosis – suggesting that Mcl-1 downregulation is a necessary event in the p53-independent apoptotic process. Thus, we identify a p53 family-independent mechanism of E2F1-induced apoptosis in which E2F1 directly represses Mcl-1 expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC . 1997 Science 277: 370–372
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . 1998 Nature 395: 124–125
Cartwright P, Muller H, Wagener C, Holm K, Helin K . 1998 Oncogene 17: 611–623
Cecconi F, Alvarez-Bolada G, Meyer BI, Roth KA, Gruss P . 1998 Cell 94: 727–737
Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, Yen JJ, Yang-Yen HF . 1998 Mol. Cell. Biol. 18: 4883–4898
Cress WD, Johnson DG, Nevins JR . 1993 Mol. Cell. Biol. 13: 6314–6325
DeGregori J, Kowalik T, Nevins JR . 1995 Mol. Cell. Biol. 15: 4215–4224
Dong YB, Yang HL, Jane M, Liu TJ, Stilwell A, Atienza Jr C, McMasters KM . 1999 Cancer 86: 2021–2033
Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM, Orkin SH, Greenberg ME . 1996 Cell 85: 549–561
Flores AM, Kassatly RF, Cress WD . 1998 Oncogene 16: 1289–1298
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP . 1998 Nat. Med. 4: 685–690
Furukawa Y, Terui Y, Sakoe K, Ohta M, Saito M . 1994 J. Biol. Chem. 269: 26249–26258
Harbour JW, Dean DC . 2000 Genes Dev. 14: 2393–2409
He Y, Armanious MK, Thomas MJ, Cress WD . 2000 Oncogene 19: 3422–3433
Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A . 1992 Cell 70: 337–350
Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Cleveland JL . 1995 Mol. Cell. Biol. 15: 6864–6874
Holmberg C, Helin K, Sehested M, Karlstrom O . 1998 Oncogene 17: 143–155
Honda R, Tanaka H, Yasuda H . 1997 FEBS Lett. 420: 25–27
Honda R, Yasuda H . 1999 EMBO J. 18: 22–27
Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X . 1997 Genes Dev. 11: 1840–1852
Hsu SY, Hsueh AJ . 2000 Physiol. Rev. 80: 593–614
Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ . 1997 Proc. Natl. Acad. Sci. USA 94: 12401–12406
Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC . 1997 Cancer Res. 57: 4722–4726
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG . 2000 Nature 407: 645–648
Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A, Heimbrook DC . 1993 Mol. Cell. Biol. 13: 7802–7812
Johnson DG, Schwarz JK, Cress WD, Nevins JR . 1993 Nature 365: 349–352
Kaelin Jr WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, Livingston DM, Flemington EK . 1992 Cell 70: 351–364
Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD . 1997 Science 275: 1132–1136
Korsmeyer SJ . 1999 Cancer Res. 59: 1693s–1700s
Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR . 1998 Cell Growth Differ. 9: 113–118
Kowalik TF, DeGregori J, Schwarz JK, Nevins JR . 1995 J. Virol. 69: 2491–2500
Kubbutat MH, Jones SN, Vousden KH . 1997 Nature 387: 299–303
La Thangue NB . 1996 Biochem. Soc. Trans. 24: 54–59
Lee CW, Sorensen TS, Shikama N, La Thangue NB . 1998 Oncogene 16: 2695–2710
Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N, Helin K . 1993 Mol. Cell. Biol. 13: 7813–7825
Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR . 2000 Mol. Cell. Biol. 20: 3626–3632
Leu CM, Chang C, Hu C . 2000 Oncogene 19: 1665–1675
Liu TJ, Wang M, Breau RL, Henderson Y, El-Naggar AK, Steck KD, Sicard MW, Clayman GL . 1999 Cancer Gene Ther. 6: 163–171
Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK . 1996 Cancer Res. 56: 40–43
Miyashita T, Reed JC . 1995 Cell 80: 293–299
Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H, Helin K . 2001 Nat. Cell. Biol. 3: 552–558
Moulding DA, Giles RV, Spiller DG, White MR, Tidd DM, Edwards SW . 2000 Blood 96: 1756–1763
Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K . 2001 Genes Dev. 15: 267–285
Ohtani K, DeGregori J, Nevins JR . 1995 Proc. Natl. Acad. Sci. USA 92: 12146–12150
Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH . 1997 Genes Dev. 11: 1853–1863
Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH . 1999 Mol. Cell. 4: 771–781
Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG . 1998 Proc. Natl. Acad. Sci. USA 95: 8858–8863
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . 1998 Cell 92: 713–723
Qin XQ, Livingston DM, Kaelin Jr WG, Adams PD . 1994 Proc. Natl. Acad. Sci. USA 91: 10918–10922
Reed JC . 1997 Nature 387: 773–776
Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW . 1994 Cancer Res. 54: 6348–6352
Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A, Weinberg RA . 1995 Proc. Natl. Acad. Sci. USA 92: 2403–2407
Shan B, Lee WH . 1994 Mol. Cell. Biol. 14: 8166–8173
Stiewe T, Putzer BM . 2000 Nat. Genet. 26: 464–469
Takahashi Y, Rayman JB, Dynlacht BD . 2000 Genes Dev. 14: 804–816
Tao W, Levine AJ . 1999 Proc. Natl. Acad. Sci. USA 96: 6937–6941
Tao Y, Kassatly RF, Cress WD, Horowitz JM . 1997 Mol. Cell. Biol. 17: 6994–7007
Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T . 1998 Mol. Cell. 2: 293–304
Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF . 1999 Mol. Cell. Biol. 19: 6195–6206
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D . 1999 Nat. Cell. Biol. 1: 20–26
Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ . 2000 Mol. Cell. Biol. 20: 5797–5807
Wu X, Levine AJ . 1994 Proc. Natl. Acad. Sci. USA 91: 3602–3606
Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T . 1998 Nat. Genet. 18: 360–364
Yamasaki L, Jacks T, Bronson R, Goilot E, Harlow E, Dyson NJ . 1996 Cell 85: 537–548
Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM . 2000 Clin. Cancer Res. 6: 1579–1589
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X . 1997 Science 275: 1129–1132
Zaika A, Irwin M, Sansome C, Moll UM . 2001 J. Biol. Chem. 276: 11310–11316
Zhang Y, Xiong Y, Yarbrough WG . 1998 Cell 92: 725–734
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack D, Levine AJ . 2000 Genes Dev. 14: 981–993
Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NG, Craig RW . 1998 Blood 92: 3226–3239
Zhou P, Qian L, Kozopas KM, Craig RW . 1997 Blood 89: 630–643
Zhu JW, DeRychere D, Li FX, Wan YY, DeGregori J . 1999 Cell Growth Differ. 10: 829–838
Acknowledgements
We thank Ronnie Moorer for technical assistance, Dr Aaron Osborne for helpful advice regarding the ChIP assays, and Drs Richard Jove, Teresita Munoz-Antonia, and PK Burnette for helpful scientific discussion, shared reagents, and comments on the manuscript. We also thank Dr Shrikant Mane, Dr Lanming Zhang and Dr Marybeth Colter, and Jodi Kroeger of Moffitt Core Facilities who performed microarray, DNA sequencing, and flow cytometry experiments, respectively. This work was supported by NCI Grant #CA78214 to WD Cress, by American Heart Association Southern Research Consortium Fellowship #9850018FL to R Croxton, and by the H. Lee Moffitt Cancer Center and Research Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Croxton, R., Ma, Y., Song, L. et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21, 1359–1369 (2002). https://doi.org/10.1038/sj.onc.1205157
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205157
Keywords
This article is cited by
-
MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation
Cell Death & Disease (2020)
-
Comparing effects of CDK inhibition and E2F1/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury
Cell Death & Disease (2018)
-
Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells
Apoptosis (2016)
-
Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
Cell Death & Disease (2014)
-
Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia
Oncogene (2013)